PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

TNF Inhibitors Lay the Groundwork for the Next Generation of Disease-Modifying Anti-Rheumatic Drugs Finds Frost & Sullivan - Huge market potential drives pharmaceutical and biotechnology companies to develop affordable alternatives with superior efficacy - healthcare.frost.com
TNF Inhibitors Lay the Groundwork for the Next Generation of Disease-Modifying Anti-Rheumatic Drugs Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2012/12/05 - Huge market potential drives pharmaceutical and biotechnology companies to develop affordable alternatives with superior efficacy - healthcare.frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for drug classes with excellent safety and efficacy profiles. While tumor necrosis factor (TNF) inhibitors have greatly enhanced the treatment of these incurable chronic conditions, their unpredictable and inconsistent efficacy as well as their high cost, potential side effects, and uncomfortable mode of delivery (by injection) are driving the need for alternative therapies.

New analysis from Frost & Sullivan's (healthcare.frost.com) The United States Rheumatic Diseases Therapeutics Market research finds that rheumatic disease therapeutics prescribed as add-on therapies to background standard therapies earned revenues of approximately $8.99 billion in 2011 and estimates this to reach $14.04 billion by 2017. Frost & Sullivan has also analyzed sub-segments of the U.S. rheumatic diseases therapeutics market, including psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis pharmacotherapeutics.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

Although TNF inhibitors have improved the lives of millions of rheumatic disease patients, there is still a vast, underserved patient pool that does not respond to this class of drugs. This huge market potential is driving pharmaceutical and biotechnology companies with immunology and inflammatory disease expertise to develop affordable alternatives with better efficacy.

"TNF inhibitors are currently the only add-on treatment option for psoriatic arthritis and ankylosing spondylitis patients, many of whom do not respond to this class and have no alternatives," said Frost & Sullivan Senior Industry Analyst Deborah Toscano. "New agents hope to offer patient-friendly alternatives to TNF inhibitors with additional benefits such as oral administration or better tolerability, with the ultimate goal of improving long-term clinical outcomes."

While no area of pharmacotherapeutics is without need of improvement, the unmet needs for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis have significantly decreased with the availability of TNF inhibitors. Thus, the main challenge for new entrants is the entrenchment of TNF inhibitors within the medical and regulatory communities.

"To gain acceptance from regulatory authorities, clinicians, and patients, emerging therapies must demonstrate economic benefits and a higher degree of safety over TNF inhibitors," noted Toscano. "Companies must also effectively market the safety and efficacy profiles as well as the robust clinical history of their drugs to raise awareness and gain the confidence of prescribing rheumatologists, patients and payors."

The United States Rheumatic Diseases Therapeutics Market is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: U.S. Market for Ankylosing Spondylitis Pharmacotherapy, U.S. Market for Psoriatic Arthritis Pharmacotherapy, U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments, Rheumatoid Arthritis Therapeutics Market in Australia, and Rheumatoid Arthritis Therapeutics Market in India. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation

The United States Rheumatic Diseases Therapeutics Market / NAF0-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


TNF Inhibitors Lay the Groundwork for the Next Generation of Disease-Modifying Anti-Rheumatic Drugs Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Britni Myers 
210-477-8481 britni.myers[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)